- Home
- ADPT vs IRON Comparison
ADPT vs IRON Comparison
Compare ADPT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- IRON
- Stock Information
- Founded
- ADPT 2009
- IRON 2017
- Country
- ADPT United States
- IRON United States
- Employees
- ADPT N/A
- IRON N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- ADPT Health Care
- IRON Health Care
- Exchange
- ADPT Nasdaq
- IRON Nasdaq
- Market Cap
- ADPT 1.8B
- IRON 2.0B
- IPO Year
- ADPT 2019
- IRON N/A
- Fundamental
- Price
- ADPT $12.85
- IRON $60.76
- Analyst Decision
- ADPT Strong Buy
- IRON Strong Buy
- Analyst Count
- ADPT 8
- IRON 10
- Target Price
- ADPT $12.38
- IRON $97.80
- AVG Volume (30 Days)
- ADPT 1.8M
- IRON 299.1K
- Earning Date
- ADPT 08-05-2025
- IRON 08-07-2025
- Dividend Yield
- ADPT N/A
- IRON N/A
- EPS Growth
- ADPT N/A
- IRON N/A
- EPS
- ADPT N/A
- IRON N/A
- Revenue
- ADPT $205,216,000.00
- IRON N/A
- Revenue This Year
- ADPT $32.76
- IRON N/A
- Revenue Next Year
- ADPT $15.81
- IRON N/A
- P/E Ratio
- ADPT N/A
- IRON N/A
- Revenue Growth
- ADPT 21.60
- IRON N/A
- 52 Week Low
- ADPT $3.98
- IRON $30.82
- 52 Week High
- ADPT $13.52
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- ADPT 57.00
- IRON 56.26
- Support Level
- ADPT $12.62
- IRON $59.74
- Resistance Level
- ADPT $13.25
- IRON $63.51
- Average True Range (ATR)
- ADPT 0.55
- IRON 2.05
- MACD
- ADPT -0.05
- IRON -0.00
- Stochastic Oscillator
- ADPT 58.13
- IRON 44.17
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.